Centro de Transfusion de Galicia, Santiago de Compostela, Spain.
Transfus Med Hemother. 2013 Feb;40(1):44-8. doi: 10.1159/000345679. Epub 2013 Jan 3.
The Mirasol pathogen reduction technology (PRT) system uses riboflavin and ultraviolet light and is currently approved and used in Europe for the treatment of platelets and plasma. Mirasol treatment is intended to reduce the infectious pathogen load and to inactivate leukocytes in blood products. Our objective was to evaluate buffy coat platelet concentrates (BCPCs) prepared with platelet additive solution (PAS) and treated with the Mirasol system and to examine the effects on platelet cell quality during storage.
26 BCPCs were prepared and split, creating 13 paired control and test units. The test units were treated with the Mirasol system and the platelet quality was assessed in all units over 7 days of storage.
All products met the incoming specifications for Mirasol treatment, and the pH of all Mirasol-treated BCPCs in PAS met the requirements of the Council of Europe guidelines throughout storage. Analysis of lactate production and glucose consumption rates, CD62p expression and cytokines indicates enhanced cellular metabolism in treated platelets, but the levels were within previously published ranges.
While Mirasol-treated BCPCs in PAS had increased metabolism and activation compared to controls, the results indicate that these units can be stored for 7 days with acceptable cell quality.
Mirasol 病原体减少技术 (PRT) 系统使用核黄素和紫外线，目前已在欧洲获得批准并用于血小板和血浆的治疗。Mirasol 处理旨在降低血液制品中的感染病原体负荷并灭活白细胞。我们的目的是评估使用血小板添加剂溶液 (PAS) 制备并用 Mirasol 系统处理的浓缩血小板 (BCPC)，并研究储存过程中对血小板细胞质量的影响。
制备并分离了 26 个 BCPC，创建了 13 对对照和测试单元。对测试单元进行 Mirasol 处理，并在所有单元中储存 7 天期间评估血小板质量。
所有产品均符合 Mirasol 处理的来料规格，所有在 PAS 中用 Mirasol 处理的 BCPC 的 pH 值在整个储存过程中均符合欧洲理事会指南的要求。对乳酸盐生成和葡萄糖消耗率、CD62p 表达和细胞因子的分析表明，处理后的血小板代谢增强，但水平处于先前发表的范围内。
尽管与对照相比，在 PAS 中用 Mirasol 处理的 BCPC 代谢和激活增加，但结果表明这些单位可以在可接受的细胞质量下储存 7 天。
